tailieunhanh - Báo cáo khoa học: "Robotic image-guided reirradiation of lateral pelvic recurrences: preliminary result"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Radiation Oncology cung cấp cho các bạn kiến thức về ngành y đề tài: Robotic image-guided reirradiation of lateral pelvic recurrences: preliminary results. | Dewas et al. Radiation Oncology 2011 6 77 http content 6 1 77 RADIATION ONCOLOGY RESEARCH Open Access Robotic image-guided reirradiation of lateral pelvic recurrences preliminary results 1 1 Sylvain Dewas Jean Emmanuel Bibault Xavier Mirabel Philippe Nickers Bernard Castelain Thomas Lacornerie1 Hajer Jarraya4 and Eric Lartigau1 Abstract Background The first-line treatment of a pelvic recurrence in a previously irradiated area is surgery. Unfortunately few patients are deemed operable often due to the location of the recurrence usually too close to the iliac vessels or the associated surgical morbidity. The objective of this study is to test the viability of robotic image-guided radiotherapy as an alternative treatment in inoperable cases. Methods Sixteen patients previously treated with radiotherapy were reirradiated with CyberKnife for lateral pelvic lesions. Recurrences of primary rectal cancer 4 patients anal canal 6 uterine cervix cancer 4 endometrial cancer 1 and bladder carcinoma 1 were treated. The median dose of the previous treatment was 45 Gy EqD2 range 20 to 96 Gy . A total dose of 36 Gy in six fractions was delivered with the CyberKnife over three weeks. The responses were evaluated according to RECIST criteria. Results Median follow-up was months to months . The actuarial local control rate was at one year. Median disease-free survival was months after CyberKnife treatment. The actuarial one-year survival rate was 46 . Acute tolerance was limited to digestive grade 1 and 2 toxicities. Conclusions Robotic stereotactic radiotherapy can offer a short and well-tolerated treatment for lateral pelvic recurrences in previously irradiated areas in patients otherwise not treatable. Efficacy and toxicity need to be evaluated over the long term but initial results are encouraging. Background Cancers such as prostate adenocarcinoma epidermoid carcinoma of the uterine cervix and adenocarcinoma of the rectum .